Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tuberculosis

Supported pathogenM. tuberculosisMycobacterium tuberculosis

Medicines already documented

Documented evidence

Registered studies whose listed conditions mention “tuberculosis”, “mycobacterium tuberculosis”, “tb”, “latent tb”.

Show all 80

Laboratory measurements against M. tuberculosis recorded in ChEMBL.

Show all 54

Other medicines to investigate

AI prediction · nothing measured

Approved medicines with AI-predicted activity ≥40% against M. tuberculosis that are not already antimicrobials, have no registered study for this condition and have no laboratory record against it. Each shows what it is already used for. They were surfaced computationally for further investigation and are not presented as established treatments for this condition.

M. tuberculosis has 870 repurposing candidates in all. 35 are already listed above, with a registered study for this condition or a laboratory record, so the other 835 are listed here.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Every repurposing candidate for M. tuberculosis, including those with documented evidence →

Registered studies

A registration describes a study; it does not establish a positive result.

When these studies started244 of 249 have a start date · most in 2023 (19)
199420102026

  • Treating Tuberculosis With the Lipid Lowering Drug Atorvastatin in Nigeria(ATORvastatin in Pulmonary TUBerculosis)

    NCT04721795 · start 2021-01-19

    Registered record
    Registry ID
    NCT04721795
    Conditions
    Tuberculosis, Pulmonary; Tuberculosis
    Interventions
    Atorvastatin with standard anti tuberculosis drugs; Standard anti tuberculosis drugs only
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2021-01-19
    Completion
    2022-06-30
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary; Tuberculosis
    InterventionAtorvastatin with standard anti tuberculosis drugs; Standard anti tuberculosis drugs only
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Phenotyping of High Dose Rifampicin

    NCT04525235 · start 2021-01-07

    Registered record
    Registry ID
    NCT04525235
    Conditions
    Tuberculosis
    Interventions
    phenotyping cocktail; rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-01-07
    Completion
    2021-08-12
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    Interventionphenotyping cocktail; rifampicin
    PhasePhase 1
    Registry statusCompleted

  • Economic Evaluation of New MDR TB Regimens

    NCT04207112 · start 2020-10-20

    Registered record
    Registry ID
    NCT04207112
    Conditions
    Multi-drug Resistant Tuberculosis; Extensively Drug-Resistant Tuberculosis; Pulmonary Tuberculoses
    Interventions
    Bedaquiline; Pretomanid; Moxifloxacin; Linezolid; Clofazimine; Standard Drugs
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2020-10-20
    Completion
    2022-08-25
    Enrolment
    73

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMulti-drug Resistant Tuberculosis; Extensively Drug-Resistant Tuberculosis; Pulmonary Tuberculoses
    InterventionBedaquiline; Pretomanid; Moxifloxacin; Linezolid +2 more
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Short Course Rifapentine and Isoniazid for the Preventive Treatment for Latent Genital Tuberculosis

    NCT04528277 · start 2020-09-01

    Registered record
    Registry ID
    NCT04528277
    Conditions
    Infertility, Female; Recurrent Implantation Failure; Genital Tuberculoses, Female; Genital Tuberculosis, Latent
    Interventions
    rifapentine plus isoniazid
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2020-09-01
    Completion
    2022-09-01
    Enrolment
    1,050

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility, Female; Recurrent Implantation Failure; Genital Tuberculoses, Female; Genital Tuberculosis, Latent
    Interventionrifapentine plus isoniazid
    PhasePhase 3
    Registry statusUnknown

  • Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)

    NCT04485156 · start 2020-09

    Registered record
    Registry ID
    NCT04485156
    Conditions
    Tuberculosis, Pulmonary
    Interventions
    High-dose rifampicin; Isoniazid; Pyrazinamide; Ethambutol; Rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2020-09
    Completion
    2026-12
    Enrolment
    926

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary
    InterventionHigh-dose rifampicin; Isoniazid; Pyrazinamide; Ethambutol +1 more
    PhasePhase 3
    Registry statusNot yet recruiting

  • Options for Delivering Isoniazid-Rifapentine (3HP) for TB Prevention (3HP Options Implementation Trial)

    NCT03934931 · start 2020-07-13

    Registered record
    Registry ID
    NCT03934931
    Conditions
    Tuberculosis; Latent Tuberculosis; HIV/AIDS
    Interventions
    Streamlined weekly DOT visits; Weekly DOT visit reminders; Cost reimbursement DOT; 99DOTS; Weekly SAT dosing reminders/check-ins; Cost reimbursement SAT
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-07-13
    Completion
    2025-01-13
    Enrolment
    1,656

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Latent Tuberculosis; HIV/AIDS
    InterventionStreamlined weekly DOT visits; Weekly DOT visit reminders; Cost reimbursement DOT; 99DOTS +2 more
    PhaseNot applicable
    Registry statusCompleted

  • Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)

    NCT03867136 · start 2020-06-01

    Registered record
    Registry ID
    NCT03867136
    Conditions
    Multidrug Resistant Tuberculosis
    Interventions
    PZA sensitivity guided ultra-short all Oral Regimen; Standardized Shorter Regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-06-01
    Completion
    2024-08-10
    Enrolment
    354

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultidrug Resistant Tuberculosis
    InterventionPZA sensitivity guided ultra-short all Oral Regimen; Standardized Shorter Regimen
    PhasePhase 4
    Registry statusCompleted

  • Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)

    NCT03896685 · start 2020-04-06

    Registered record
    Registry ID
    NCT03896685
    Conditions
    Tuberculosis, Multidrug-Resistant; Tuberculosis; Pulmonary Tuberculoses; Mycobacterial Infections; Bacterial Infections; Gram-Positive Bacterial Infections
    Interventions
    Bedaquiline 100 MG; Delamanid 50 MG Oral Tablet; Clofazimine 100 MG Oral Capsule; Linezolid 600Mg Tab; Control arm MDR-TB regimen, designed according to latest WHO guidelines
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-04-06
    Completion
    2024-12-31
    Enrolment
    323

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Multidrug-Resistant; Tuberculosis; Pulmonary Tuberculoses; Mycobacterial Infections +2 more
    InterventionBedaquiline 100 MG; Delamanid 50 MG Oral Tablet; Clofazimine 100 MG Oral Capsule; Linezolid 600Mg Tab +1 more
    PhasePhase 3
    Registry statusCompleted

  • Statin Adjunctive Therapy for TB

    NCT03456102 · start 2020-03-09

    Registered record
    Registry ID
    NCT03456102
    Conditions
    Tuberculosis
    Interventions
    Pravastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-03-09
    Completion
    2022-08-31
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionPravastatin
    PhasePhase 2
    Registry statusCompleted

  • Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia

    NCT03915366 · start 2020-03-01

    Registered record
    Registry ID
    NCT03915366
    Conditions
    Pneumonia; HIV/AIDS; Tuberculosis; Cytomegalovirus Infections
    Interventions
    Valganciclovir Oral Solution [Valcyte]; Tuberculostatic Agents
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2020-03-01
    Completion
    2025-01-31
    Enrolment
    563

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia; HIV/AIDS; Tuberculosis; Cytomegalovirus Infections
    InterventionValganciclovir Oral Solution [Valcyte]; Tuberculostatic Agents
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis

    NCT04176250 · start 2020-01-16

    Registered record
    Registry ID
    NCT04176250
    Conditions
    Pulmonary Tuberculosis
    Interventions
    TBA-7371; TBA-7371; TBA-7371; TBA-7371; TBA-7371; HRZE
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-01-16
    Completion
    2022-10-05
    Enrolment
    93

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionTBA-7371; TBA-7371; TBA-7371; TBA-7371 +2 more
    PhasePhase 2
    Registry statusCompleted

  • Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid

    NCT04309656 · start 2020-01-14

    Registered record
    Registry ID
    NCT04309656
    Conditions
    Multi-drug Resistant Tuberculosis
    Interventions
    Pretomanid
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-01-14
    Completion
    2020-02-28
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMulti-drug Resistant Tuberculosis
    InterventionPretomanid
    PhasePhase 1
    Registry statusCompleted

  • The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants

    NCT04424264 · start 2019-12-05

    Registered record
    Registry ID
    NCT04424264
    Conditions
    HIV-1-infection; Tuberculosis
    Interventions
    Phase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid; Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid; Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-12-05
    Completion
    2020-10-30
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection; Tuberculosis
    InterventionPhase 1: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz coadministered with Rifampicin/Isoniazid; Phase 2: Tenofovir alafenamide/Lamivudine/Efavirenz coadministered with Rifampicin/Isoniazid; Phase 3: Tenofovir disoproxil fumarate/Emtricitabine/Efavirenz
    PhasePhase 1
    Registry statusCompleted

  • BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)

    NCT04044001 · start 2019-11-15

    Registered record
    Registry ID
    NCT04044001
    Conditions
    Pulmonary Tuberculoses; Other Specified Pulmonary Tuberculosis
    Interventions
    BTZ-043; Rifafour e-275®; Probe Drug Cocktail; Dolutegravir 50mg Tab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2019-11-15
    Completion
    2022-05-31
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculoses; Other Specified Pulmonary Tuberculosis
    InterventionBTZ-043; Rifafour e-275®; Probe Drug Cocktail; Dolutegravir 50mg Tab
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Tuberculosis Clinical Trials Consortium Study 35

    NCT03730181 · start 2019-11-12

    Registered record
    Registry ID
    NCT03730181
    Conditions
    Latent Tuberculosis
    Interventions
    Rifapentine; Isoniazid
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2019-11-12
    Completion
    2025-05-15
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLatent Tuberculosis
    InterventionRifapentine; Isoniazid
    PhasePhase 1 / Phase 2
    Registry statusCompleted